GE Healthcare and Rapidscan Pharma Solutions have introduced regadenoson, marketed as Rapiscan, to facilitate myocardial perfusion scintigraphy (MPS) to diagnose coronary artery disease for patients unable to exercise.

Exclusively available in the U.K., Rapiscan increases coronary blood flow to simulate exercise-induced stress for MPS. The pharmacological stress agent is administered as a 10-second injection, with a uniform dose for patients of all sizes and without the need for an infusion pump, extension line or infusion line set-up, GE and Rapidscan said.